Risks and Enforcement Issues of Testimonials is Subject of Presentation

August 23, 2011

By Michelle Axelrod


Michelle D. Axelrod, Vice President of Porzio Pharmaceutical Services and Principal of Porzio Bromberg & Newman, was a featured speaker at CBI’s recent 2nd Annual Forum on Social Media Regulations and Compliance.  The program, presented with her Porzio colleague Justin C. Hallberg, was entitled, “Risks and Enforcement Related to the Use of Testimonials.”

The increased use of social media to promote products, including the use of testimonials, raises a number of issues that continue to be a focus of FDA, FTC and other government entities. 

For a copy of the slides Ms. Axelrod and Mr. Hallberg used in the presentation, please email info@pbnlaw.com with the subject line, “Please send Axelrod/Hallberg slides.”

Porzio Pharmaceutical Services recently released its DDMAC database that contains searchable summaries of untitled and warning letters issued to life sciences companies by the FDA’s Division of Drug Marketing, Advertising  and Communications (DDMAC). 

Letters are categorized in a variety of ways, including date of issuance, type of promotional material, and identified violation.  Subscribers to this database may search for specific letters and related violations to assess prescription drug advertising and promotional labeling enforcement trends.

More Resources